Abstract:Objective. To explore the diagnostic value of serum anti-Mullerian hormone (AMH) for patients with premature ovarian insufficiency (POI) and premature ovarian failure (POF). Methods. Totally, 125 women with menstrual disorder treated in the Obstetrics and Gynecology Department of Ningbo Women & Children Hospital between January 2020 and December 2021 were enrolled. Among them, based on the follicle-stimulating hormone (FSH) level, 54 patients ( 25 IU / L < FSH ≤ 40 IU / L ) were assigned to the POI group, and 71 patients ( FSH > 40 IU / L ) were assigned to the POF group. In addition, 72 individuals who went physical examination in the hospital and showed normal menstrual cycle were selected as the control (CON) group. Serum AMH in each group was quantified via enzyme-linked immunosorbent assay (ELISA) and Beckman Coulter Access active immunoassay analyzer, and the levels of serum neutral hormones [luteinizing hormone (LH), FSH, as well as estradiol (E2)] in each group were detected through the electrochemiluminescence method. The difference between AMH level acquired by the latest automatic method and that acquired by the traditional manual ELISA was compared, and the correlation of serum AMH with sex hormones was analyzed. In addition, receiver-operating characteristic (ROC) curves were drawn for determining the diagnostic value of serum AHM for POI ad POF. Results. Beckman Coulter Access quantified AMH more accurately and fastly (Beckman Coulter Access: 35 minutes; manual quantification: 3-4 hours) and was more sensitive than ELISA, with a requirement to less serum. The levels of serum AMH and E2 in the POF group were 0.04 ± 0.10 ng/mL and 35.16 ± 53.06 ng/mL, respectively, which were notably lower than those in the POI group (( 0.69 ± 1.46 ) ng/mL and ( 3.96 ± 2.82 ) ng/mL) and CON group (( 76.31 ± 97.84 ) ng/mL and ( 113.19 ± 114.84 ) ng/mL). The LH and FSH levels in the POF group were 37.86 ± 19.44 IU/L and 75.05 ± 35.31 IU/L, which were higher than those in POI group (( 22.66 ± 26.15 ) IU/L and ( 11.30 ± 17.05 ) IU/L) and the CON group (( 29.81 ± 4.45 ) IU/L and ( 6.78 ± 3.45 ) IU/L) ( P < 0.05 ). The POI group showed a notably lower serum AMH level and notably higher LH and FSH levels than the CON group ( P < 0.05 -Abstract Truncated-

Correlation Between Hyaluronic Acid in Follicular Fluid and Oocyte Retrieval Outcome in Patients with Diminished Ovarian Reserve

Anti-Müllerian hormone for prediction of ovarian response in Chinese infertile women undergoing IVF/ICSI cycles: a prospective, multi-centre, observational study

Role of Anti-Müllerian Hormone and Testosterone in Follicular Growth: a Cross-Sectional Study.

Serum LH Levels on hCG Trigger Day Affect IVF Outcomes Intensified by Poor Ovarian Reserve and Advanced Age

The effect of progesterone level prior to oocyte retrieval on the numbers of oocytes retrieved and embryo quality in IVF treatment cycles: an analysis of 2,978 cycles

Correlation Of Serum Vitamin D Levels With Ovarian Reserve Markers In Patients With Primary Ovarian Insufficiency

The Association of AMH Level with the Number and Quality of Oocytes in Women Undergoing IVF/ICSI: A Single-Center Study

Elevated Follicular Cortisone Level is a Negative Predictor of Clinical Pregnancy in Women Undergoing Fresh Embryo Transfer

The Role of Follicular Fluid Anti-Mullerian Hormone in Success Rate of Intracytoplasmic Sperm Injection

Expression of Gonadotrophin Receptor and Influencing Factors among Different Ovarian Reserve Patients

Study of Serum Anti-Mullerian Hormone in the Diagnosis of Ovarian Reserve Function in Patients with Premature Ovarian Insufficiency

Correlation of Follicle-stimulating Hormone, Anti-Mullerian Hormone, and Antral Follicle Count with Age in Ovarian Reserve Testing

Discordance between antral follicle counts and anti-Müllerian hormone levels in women undergoing in vitro fertilization

Serum Levels of Anti-Müllerian Hormone Influence Pregnancy Outcomes Associated with Gonadotropin-Releasing Hormone Antagonist Treatment: a Retrospective Cohort Study

Factors improved clinical outcomes in patients < 38 years with diminished ovarian reserve and low oocyte retrieval: a retrospective study

Diminished ovarian reserve associates with pregnancy and birth outcomes after IVF: a retrospective cohort study

Anti-Mullerian Hormone as a Marker of Ovarian Reserve and Function

Using anti-Müllerian hormone to predict premature ovarian insufficiency: a retrospective cross-sectional study

The relationship between serum anti-Müllerian hormone levels and the follicular arrest for women with polycystic ovary syndrome

Positive Effect of 25-Hydroxyvitamin D (25(OH)D) Levels in Follicular Fluid on Embryonic Developmental Potential in Diminished Ovarian Reserve (DOR) Patients Undergoing Microstimulation

The Predictive Levels of Serum Anti-Müllerian Hormone and the Combined Index of the Number of Retrieved Oocytes and Good-Quality Embryos in Advanced-Age Infertile Women.